MINIMALLY INVASIVE GYNECOLOGIC PROCEDURES: Edited by Matthew T. Siedhoff and Nisse V. ClarkTopical hemostatic and tissue-sealing agents in gynecologic surgeryCullifer, Rachel M.; Makai, Gretchen; Pacis, Michelle; Huynh, TerriAuthor Information Division of Minimally Invasive Gynecologic Surgery, Department of Obstetrics and Gynecology, Christiana Care Health System, Newark, Delaware, USA Correspondence to Rachel M. Cullifer, MD, Christiana Care Health System, 4755 Ogletown-Stanton Road, Newark, DE 19718, USA. Tel: +1 302 623 4410; e-mail: firstname.lastname@example.org Current Opinion in Obstetrics and Gynecology: August 2020 - Volume 32 - Issue 4 - p 285-291 doi: 10.1097/GCO.0000000000000632 Buy Metrics Abstract Purpose of review To review current topical hemostatic agent use and how it pertains to gynecologic surgery. Recent findings Recent literature suggests some benefit of topical hemostatic agents (THA). THAs confer reduced bleeding and shorter operating room time in women undergoing hysterectomy for cancer and in abdominal myomectomy. THA use in women undergoing ovarian cystectomy is associated with a decreased reduction in ovarian reserve. Potential complications of THA use include abscess formation, small bowel obstruction, inflammation, allergic reaction, and transmission of blood-borne pathogens. Evidence for use of THA in benign minimally invasive gynecologic surgery (MIGS) procedures is lacking. Summary Although evidence exists for the efficacy of THA in reducing blood loss and operating times across surgical subspecialties, specific, appropriate, and efficacious use of THAs in gynecologic surgery remains ill-defined. Knowledge of their mechanisms of action and potential complications should enable surgeons to optimize desired effects and minimize harm. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.